Search results: (10000)
News Panitumumab in 1st Line in Older Patients – Results of the PANDA Study
The phase II PANDA study evaluated the regimens FOLFOX + panitumumab versus 5-FU + panitumumab in the 1st line treatment of patients with wt-RAS/BRAF metastatic colorectal cancer (mCRC).
News Two Is Not Enough: Efficacy of Alemtuzumab in Subsequent Cycles
The goal of the recent pooled analysis of the CARE-MS and TOPAZ study results published in the journal Multiple Sclerosis was to evaluate the efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS) who received alemtuzumab in additional cycles beyond the first 2 cycles.
News Experiences with AHA in Two Czech Centers and Risk Factor Evaluation
This summer, the journal Haemophilia published the results of an analysis of data from a relatively large Czech cohort of patients with acquired hemophilia A (AHA). The goal was to identify risk factors associated with early death and AHA relapse. Additionally, the authors addressed the question of the effect of higher doses of corticosteroids on treatment outcomes and patient mortality.
News Does Ixekizumab Have Long-term Effects on Improving Psoriatic Arthritis Symptoms?
The extension of the SPIRIT-P2 study brought results of ixekizumab in patients with psoriatic arthritis (PsA) after 3 years of use. The data below were presented as a poster presentation at the annual congress of the European League Against Rheumatism (EULAR), which was held virtually in June 2020.
News Did the Extension of the TOWER Study Confirm the Position of Teriflunomide?
The results of the TOWER study extension were published this August in the prestigious journal Multiple Sclerosis and Related Disorders. So, how did teriflunomide fare in this recent evaluation for the treatment of relapsing-remitting multiple sclerosis?
News COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care focused on seriously ill patients, the pandemic also affects the care of chronic patients, including those with hemophilia. However, there is currently not much specific data available regarding experiences with COVID-19 in patients with hemophilia. The specifics of congenital bleeding disorders, especially in relation to the severe course of COVID-19, are discussed by Italian authors in their article published in the journal Seminars in Thrombosis and Hemostasis.
News Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib in the first interim analysis of the ALTA-1L study in terms of progression-free survival and improvement in health-related quality of life in patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangement. The second interim analysis results published in 2020 confirm these primary findings.
News Self-Administration of Romiplostim in Chronic Immune Thrombocytopenia: Analysis of 3 Studies
A post hoc analysis of 3 clinical studies showed that in adult patients with chronic immune thrombocytopenia (ITP), self-administration of romiplostim achieves comparable efficacy and safety as when the drug is administered by a healthcare professional.
News The Role of the Physiotherapist in the Management of Hemophilia – Defining a New Normal
Historically, the role of physiotherapy in hemophiliacs was primarily to assist patients who developed severe hemophilic arthropathies resulting from recurrent untreated or inadequately treated bleeding. Today, it has also shifted to prevention as such, although it still plays a role in significant joint bleeding or when a hemophiliac needs to undergo surgery.
News Improvement of Physical Functions in Patients with COPD in Routine Clinical Practice Using the Fixed Combination of Tiotropium/Olodaterol
The increase in exercise capacity using the fixed combination of tiotropium and olodaterol in the Respimat inhaler has already been demonstrated in clinical studies for patients with chronic obstructive pulmonary disease (COPD). Italian authors evaluated its benefit under real-world conditions and also focused on patient satisfaction with the inhaler.
News Thromboprophylaxis with Enoxaparin Reduces Mortality in Patients Hospitalized with COVID-19
Severe acute respiratory syndrome caused by COVID-19 is associated with a hypercoagulable state and an increased risk of thrombotic events. Since the beginning of the pandemic, thromboprophylaxis has been recommended for these patients despite initial insufficient evidence. In the fall of 2020, an observational study was published confirming the beneficial effect of enoxaparin on reducing mortality and the risk of ICU admission in patients with severe COVID-19.
News Tolerability and Efficacy of Eye Drops with and without Preservatives − A Comparison in Routine Clinical Practice
Insufficient patient compliance due to intolerance of the ocular preparation is a major reason for changing treatment, such as switching to preservative-free drops. The aim of the international prospective and observational study was to assess the efficacy and local tolerability within a one-year therapy of preservative-free latanoprost compared to drops containing preservatives and to determine patient satisfaction at the midpoint of treatment. During the monitoring, 3 examinations were planned: one at the study entry and two follow-up visits (at 6 and 12 months).
News In vivo monitoring of corneal changes in patients treated with and without preservative-containing glaucoma medications
A study published last year by Italian authors monitored structural changes in the corneas of patients treated with preservative-free glaucoma medication for 3 years using confocal microscopy and compared them with changes observed in patients treated with preservative-containing medications.
News Aclidinium bromide improves the quality of life for COPD patients
The ON-AIR study conducted in real practice demonstrated the benefits of aclidinium bromide for the quality of life of patients with chronic obstructive pulmonary disease (COPD). It also assessed the impact of treatment on the severity of nocturnal and morning symptoms and their impact on daily activities.
News Incidence of Allergic Diseases in Children Probably Unrelated to Air Pollution
A recently published extensive meta-analysis of 7 cohorts of children aged 4 and 8 from 5 European countries investigated the relationship between air pollution at the child's place of residence and the incidence of allergic eczema, rhinoconjunctivitis, or asthma.
News How to Communicate and Receive an Oncological Diagnosis
Communicating the truth about a patient's health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system only began to emphasize this aspect, that is, honest and open communication between doctor and patient, several years after the Velvet Revolution.
News Idarucizumab reverses the anticoagulant effect of dabigatran even in patients with impaired renal function – clinical practice commentary
Along with the results of a subanalysis of the RE-VERSE AD study, which demonstrated the efficacy of idarucizumab in reversing the anticoagulant effect of dabigatran regardless of the level of renal function impairment, the October issue of the Journal of the American College of Cardiology also featured an editorial commentary by Californian cardiologists on its conclusions.
News Can NOACs 'Compete' with Well-Managed Warfarin Treatment? Retrospective Data from Swedish Registers
The efficacy and safety of new oral anticoagulants (NOACs) in stroke prevention in atrial fibrillation have been proven by numerous studies. The quality of warfarin treatment, assessed by the 'time in therapeutic range' (TTR), ranged between 55% and 65% in these studies. The work of Swedish authors provides a comparison of patients treated with NOACs to a group on warfarin whose average TTR reached 70%.
News Metformin in New European Guidelines for Treating Patients with Diabetes and Cardiovascular Disease
The position of metformin has changed in the guidelines for the treatment of prediabetes and type 2 diabetes in individuals with cardiovascular (CV) disease, issued by the European Society of Cardiology (ESC) in collaboration with the European Association for the Study of Diabetes (EASD) in 2019. The 2019 EASD recommendations differ somewhat, thus we provide the following updated summary.
News How trends in sports evolve among hemophiliacs and to what extent they are limited by their disease
Historically, physical activity was generally not recommended for hemophiliacs; however, with evolving treatment options and prophylaxis as the gold standard of care for these patients, sports have become part of their lives in recent years. The Netherlands, traditionally supportive of sports, including for patients with chronic illnesses, presented the results of a survey on hemophilia and sports in a poster presentation at the 13th annual EAHAD congress in The Hague this February.
News Efficacy and Speed of Pain Relief in Rheumatoid Arthritis When Adding Baricitinib to Methotrexate
The phase III clinical trial RA-BEAM conducted in patients with rheumatoid arthritis (RA) inadequately controlled by methotrexate demonstrated the benefit of adding baricitinib or adalimumab compared to placebo in terms of reducing the number of swollen joints. However, baricitinib showed greater pain relief starting from week 1 compared to placebo and from week 2 compared to adalimumab. Thus, the recently published results of an analysis using the data from this study aimed to compare the proportion of patients who achieved certain pain relief thresholds, the time required for pain relief, and the relationship between the presence of inflammation and pain.
News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab
In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.
News Persistence of Treatment with Secukinumab and Ixekizumab in Patients with Moderate to Severe Psoriasis
Although IL-17 targeted drugs are increasingly used in the treatment of moderate to severe psoriasis, we currently have limited data on patient persistence with these treatments.
News European Survey on Prophylactic Treatment of Chemotherapy-Induced Nausea and Vomiting Suggests Gaps in Practice and Ways to Improve
Using recommended guidelines for antiemetic prophylaxis can prevent chemotherapy-induced nausea and vomiting (CINV). Nurses play a significant role in administering prophylactic treatment for CINV. Therefore, a survey was conducted in 16 European countries among middle medical personnel to evaluate the use of recommended antiemetic prophylaxis in oncology practice and the obstacles to its administration.
News New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?
The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly expanded in recent years. Significant changes have been brought particularly by small molecule-based therapeutic agents (inhibitors), which have shown significant efficacy in both previously untreated patients and those who have relapsed from CLL. When choosing the best treatment strategy for patients with CLL, it is of course necessary to consider the specific adverse effects of both new and previously used drugs, the overall condition of the patient, comorbidities, and the so-called individual risk of serious side effects of the drugs.